Johns Hopkins Medicine Curbs Interactions with Industry - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Johns Hopkins Medicine Curbs Interactions with Industry


ePT--the Electronic Newsletter of Pharmaceutical Technology

Last week, Johns Hopkins Medicine (JHM) adopted a new policy to protect patients by limiting the influence of pharmaceutical marketing on faculty and physicians’ decisions. The “Johns Hopkins Medicine Policy on Interaction with Industry” will take effect on July 1, 2009 and adds new restrictions on how JHM’s doctors, scientists, students, and staff interact with the pharmaceutical industry.

One of the new rules prohibits the acceptance of food or entertainment from pharmaceutical companies. Another new rule bars JHM personnel from entering into consulting agreements under which they are paid but have no real duties. The policy also declares that JHM will no long accept free samples of medicines beginning in 2010. An exception is provided, however, for samples that do not feature a brand name or manufacturer's name and that will be used for patient education.

The policy also limits pharmaceutical industry representatives’ access to JHM facilities. Representatives may visit individual physicians only at the physicians’ invitation, and the interaction must be restricted to areas that are not dedicated to patient care.

Similarly, industry representatives, who are also healthcare professionals or scientists, can provide information about their companies’ products only at the invitation of a faculty physician, according to the new policy. Presentations must occur in faculty-supervised settings that allow information to be evaluated critically.

The new policy recognizes the importance of industry gifts in supporting education, research, and patient care, but stipulates that such gifts must be deposited in a departmental account. Furthermore, the gifts must be given without conditions, and no quid pro quo arrangement will be accepted.

Continuing medical education (CME) is also addressed in the new policy. All industry-supported CME courses for credit must be managed by the Hopkins Office of CME. Noncredit educational events supported by industry will be reviewed to ensure that they comply with the Accreditation Council for Continuing Medical Education’s standards. In addition, the policy requires that the industry sponsors of all noncredit educational courses be disclosed.

The new policy prohibits Hopkins employees from speaking at industry-sponsored programs such as speakers bureaus if a company has control over the speech or uses a Hopkins faculty member as a company spokesperson. When employees give presentations that are funded by industry, the support must be fully disclosed. Employees may act as consultants for industry and offer scientific advice as long as compensation is offered at fair market value and the written contract does not conflict with JHM’s policy on conflict of commitment.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
9%
Protecting the supply chain
39%
Expedited reviews of drug submissions
9%
More stakeholder involvement
13%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here